Pfizer's stock has declined nearly 20% over five years, pushing its dividend yield to around 6%. Despite this, the company continues to pay a steady $0.43 quarterly dividend, supported by earnings that cover the payout but with tight cash flow margins. CEO Albert Bourla has committed to maintaining the dividend through upcoming challenges, including a $1.5 billion loss-of-exclusivity impact in 2026, though significant dividend hikes are unlikely until growth resumes. Investors face a mixed picture: an attractive yield driven by price weakness, solid earnings coverage, but limited buybacks and tight cash flow.
Six well-known dividend-paying companies, including Pfizer, Icahn Enterprises, and Western Union, have been distributing dividends exceeding their net income and operating cash flow for multiple years. This practice often relies on borrowing, which i...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
